Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

20152,567 citationsJournal Articlebronze Open Access

Authors

Jennifer B. Green · Duke University

M. Angelyn Bethel · University of Oxford

Paul W. Armstrong · University of Alberta

John B. Buse · University of North Carolina at Chapel Hill

Samuel S. Engel · Merck & Co., Inc., Rahway, NJ, USA (United States)

Jyotsna Garg · Clinical Research Institute

Robert Josse

Abstract

Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.).

Topics & Keywords

Diabetes Treatment and Management Peptidase Inhibition and Analysis Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 3, pp. 232-242

DOI: 10.1056/nejmoa1501352

Field-Weighted Citation Impact: 264.24